Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Holdings Inc. is poised for a favorable outlook following its acquisition by Garda Therapeutics, which presents significant premiums of 34.6% to the unaffected stock price and up to 62.2% to the 60-day volume-weighted average price, indicating strong market confidence in its long-term prospects. Additionally, the completion of the reverse split eliminates the risk of delisting from NASDAQ, ensuring compliance with minimum bid price requirements and enhancing stock stability. Furthermore, the strategic divestiture of non-Rolvedon assets to Cosette Pharmaceuticals enables Assertio to concentrate on its core oncology products, potentially optimizing its operational efficiencies and market positioning.

Bears say

Assertio Holdings Inc faces significant challenges that negatively impact its stock outlook, primarily due to the potential inability to gain additional market share for key products like ROLVEDON and Sympazan amid increasing competition. The company's recent loss on impairment of intangible assets, totaling $5.2 million, highlights concerns regarding its asset valuation and future growth prospects, particularly with legacy products losing market exclusivity. Furthermore, the anticipated decline in revenue from non-core products and a heightened risk of equity dilution creates an uncertain financial environment that undermines investor confidence.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.